CD274 and cancer: Therefore, a regain of anti-cancer-immunosurveillance using additional immunotherapies such as anti-programmed death ligand 1 (PD-L1)/PD-1 and/or anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) [6] and immune stimulants such as hyperthermia [7, 8] in multimodal treatment settings is a further step forward to get the cancer under control and to cure it.